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Abstract To the objective of this study is to evaluate the role
and toxicity of radiotherapy in the treatment of Graves
ophthalmopathy. In the years 2000–2003, 121 patients with
malignant exophthalmoswere treatedwithradiotherapyofthe
retrobulbar areatothe totaldoseof20Gyinten fractions with
a 6 MeV photon beam. The treatment was performed by the
team of the Clinic of Oncology of the Jagiellonian University
Medical College in Cracow. The radiotherapy was preceded
by intravenous steroid therapy: methylprednisolone acetate
administered at the dose of 2 g/week for four consecutive
weeks. The highest efficacy, expressed as improvement of all
ocular symptoms, was observed for the combined treatment.
Female and non-diabetic patients responded positively to the
combined treatment. Radiotherapy combined with steroid
therapy in the treatment of Graves ophthalmopathy seems to
beaneffective treatment for strictly defined indications.Inthe
treatment of Graves–Basedow disease, radiotherapy is a well-
tolerated treatment modality. Diabetes is a factor that worsens
prognosis in Graves ophthalmopathy and female sex is a
favourable factor for this condition.
Keywords Gravesophthalmopathy.Radiotherapy.
Combinedtreatment
Introduction
Graves ophthalmopathy is a complex of ocular symptoms
accompanying autoimmune thyroid diseases. In 90% of
cases, itisassociatedwithhyperthyreosis.Inthe other 10% of
cases, it is diagnosed in euthyreotic patients, and is called
ocularGravesdisease,orinhypothyreoticpatients(andthenit
is most frequently associated with Hashimoto disease) [40].
Modern imaging techniques revealed that ocular symptoms
occur in almost all patients with hyperthyreosis [11, 12, 69,
73, 74]. These are usually benign lesions (non-infiltrative
ophthalmopathy) that subside totally after normal thyroid
function is restored [11, 18, 49, 70, 73]. About 5–10% of
patients with hyperthyreosis develop Graves ophthalmopathy
of a progressive course that may lead to severe ocular
complications [28, 73, 74]. Sometimes only involvement of
oculomotor muscles is found without exophthalmos. Optic
neuropathy, corneal ulcerations and perforations with conse-
quent blindness may occur [21, 28, 73, 74].
In the treatment of infiltrative ophthalmopathy, irrespective
of thyroid function control, there is a necessity to reduce the
volume of oedematous swollen intraorbital tissues to expand
free space inside the orbit. To achieve the above glycocorti-
costeroid treatment, radiotherapy, combination of both meth-
ods or surgical orbital decompression are used [1, 7, 11, 35,
36, 42, 65, 71, 72, 73]. Surgical decompression reduces only
mechanical effects of exophthalmos and usually, sooner or
later, requires subsequent glycocorticosteroid therapy. Effec-
tiveness of glycocorticosteroids (recently administered in the
form of pulses of methylprednisolone acetate) is found to be
60% [11, 37, 58, 64, 73].
Starting from the year 1983, high doses of glycocorti-
costeroid are combined with orbital radiotherapy [5].
Glycocorticosteroid therapy provides quick improvement
of ocular symptoms and prevents transient worsening of
these symptoms as the result of radiotherapy [11, 16, 29,
42, 53, 67]. Irradiation consolidates the effects of steroid
therapy and decreases the risk of ocular symptoms relapse
[9, 11, 16, 57, 73]. Radiotherapy has unspecific anti-
inflammatory and specific immunosupressive effects on
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the immune reaction in the orbit [56, 74]. The optimal
irradiation dose in the treatment of Graves ophthalmopathy
is 20 Gy in ten fractions administered within 2 weeks [11,
27, 30, 31, 39, 56, 62, 73–75].
This paper summarizes my own experience in the
treatment of Graves ophthalmopathy.
Materials and methods
From January 2000 to December 2003, the team of the Clinic
of Oncology of the Jagiellonian University Medical College
performed radiotherapy of the retrobulbar area in 121 patients
(91 female—75.2% and 30 males—24.8%). Mean age was
55.1 years (range, 32–85). One hundred sixteen out of 121
(95.9%) patients received previously in the Clinic of Endo-
crinology intravenous treatment with methylprednisolone
acetate at the dose of 2 g/week for four consecutive weeks.
Five patients (4.1%) did not receive glycocorticosteroids
dueto:contraindications(twopatients),improvementofocular
symptoms after treatment with methimazole (except persistent
symptoms within the peribulbar soft tissue; two patients) and
due to refusal of consent for steroid treatment (one patient).
Twelve months after the treatment was completed, in 106/
121 patients ophthalmologic examination and orbital CT
scan were performed. Three out of the remaining 15 patients
died before the follow-up visit and 12 refused to undergo the
follow-up procedures. Clinical characteristics of 101 patients
subject to further analysis are presented in Table 1.
As shown in the table above, mean age in the combined
treatment group was 52 years. Female patients, non-smokers
and non-diabetics predominated. Mean time from the onset
of ocular symptoms to the treatment start was 16 months.
The majority of patients was previously treated for hyper-
thyreosis (61/101 i.e. 60.4%) and was hyperthyreotic at the
time of exophthalmos onset. However, at the moment of
referral for radiotherapy, the majority of patients had normal
fT4 and thyroid-stimulating hormone (TSH) levels.
The subsequent analysis will involvetwogroups of patients:
1. One hundred one101 patients previously treated with
intravenous steroids (assessed before radiotherapy),
2. Ninety-three patients out of 101 patients in group A
treated with the combined method, i.e., with steroid
therapy with subsequent radiotherapy to the total dose
of 20 Gy in ten fractions (assessed after radiotherapy).
Irradiation technique
Before the start of radiotherapy assessed individual celone
moulds were done for all patients. In all patients, orbital CT
scans were done for treatment planning. CT slice thickness
was 3 mm. Two opposite isocentric beam techniques were
used to cover the retrobulbar area. Beam angles were
adjusted for divergence to form coincident plane behind
lenses (Fig. 1). Extraorbital structures were individually
shielded with Wood alloy shields. Irradiation was per-
formed with a 6 MeV photon beam emitted by the
Mevatron Primus accelerator. The planned irradiation dose
was 20 Gy in ten fractions. Treatment planning was done in
a 3D treatment planning system—TMS Helax.
Assessment of treatment efficacy
The following methods were used to assess the efficacy of
the treatment: medical history, ophthalmologic examination
and CT scan of the retrobulbar areas. Ophthalmologic
examination was done before the start of the treatment and
Table 1 Characteristics of 101 patients treated with the combined
method
Mean age 52.3 years (32-81)
Sex
Males 26 (25.7%)
Females 75 (74.3%)
Time from the onset of ocular
symptoms to the start of
the combined treatment
16.8 months (4-116 months)
Smoking
No 50 (49.5%)
Yes 49 (48.5%)
Unknown 2 (2%)
Diabetes
No 89 (88.1%)
Yes 12 (11.9%)
Thyroid status at the moment
of exophthalmos diagnosis
Normal 16 (15.8%)
Hyperthyreosis 74 (73.3%)
Unknown 11 (10.9%)
Treatment of hyperthyreosis
No 17 (16.8%)
Yes 84 (83.2%)
Pre-treatment fT4 level
(normal range, 11–22 pmol/l)
Normal 74 (73.3%)
Elevated 5 (5%)
Lowered 16 (15.8%)
No data 6 (5.9%)
Pre-treatment TSH level:
(normal range, 0.2–6.5μU/mol)
Normal 70 (69.3%)
Elevated 7 (6.9%)
Lowered 24 (23.8%)
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nation the NOSPECT score system was used to define
severity of ophthalmopathy based on such parameters as:
soft tissues (i.e., conjunctiva, eyelids), exophthalmos,
oculomotor muscle dysfunction, condition of the cornea
and vision. These symptoms were attributed scores: 1–2–3,
depending on symptom severity. Eyelids and conjunctiva:
1—minor reddening of conjunctiva or moderate eyelid
oedema, 2—significant reddening of conjunctiva or major
eyelid oedema, 3—severe inflammatory condition of the
above structures. Exophthalmos was measured with exoph-
thalmometer: 20–24 mm scored—1, 24–27 mm—2, above
27 mm—3. Oculomotor muscle involvement: eye globe
mobility impairment in extreme eye positions—1, signifi-
cant impairment of eye globe mobility—2, immobilisation
of one or both eye globes—3. Cornea: single epithelial
defects (with fluorescein staining)—1, moderate epithelial
defects—2, extensive epithelial defects—3. Snellen chart
was used for vision assessment. Vision defect ranging from
0.67–0.33 scored 1, 0.32–0.10—2, below 0.10—3. CTscan of
retrobulbar areas was performed in all patients before the start
the treatment and after 12 months of treatment completion.
Based on CTof retrobulbar area the following parameters were
assessed: thickness of the recti muscles and lacrimal glands,
volume of the retrobulbar fat and optic nerve condition.
Statistical analysis
Qualitative parameters were characterised by percentage
distribution. Relationships between qualitative parameters,
including assessment of the treatment effect, were evaluated
with chi square independent test. To compare particular
treatment stages the case–control method and Fisher test
was used. p value was calculated for all tests.
Results
Evaluation of the treatment with steroids
Treatment results as assessed by ophthalmologic examina-
tion in the group of patients treated previously with
intravenous steroids (situation before radiotherapy) are
presented in Tables 2 and 3.
Based on the above table, significant improvement within
right peribulbar soft tissues following intravenous steroid
therapy may be shown (p<0.05). Nevertheless, this obser-
vation is weakened by the fact that in half of the patients,
post-treatment ophthalmologic assessment is missing.
Based on the above table, significant improvement within
left peribulbar soft tissues following intravenous steroid
therapy may be shown (p<0.05). Nevertheless, this obser-
vation is weakened by the fact that in half of the patients,
post-treatment ophthalmologic assessment is missing.
Treatment results as assessed by computed tomography
(CT) of the retrobulbar areas 12 months after treatment
completion in the group of patients treated previously with
intravenous steroid therapy.
Treatment results are presented in Table 4.
As shown in the table above, no improvement was found
within the right eye as assessed with computed tomography.
Only slight improvement of the left eye condition was
observed, in terms of reduction of the retrobulbar fat tissue.
Evaluation of efficacy of the combined treatment
Treatmentresultsasassessedbyophthalmologicexamination.
The results are presented in Tables 5 and 6.
Based on the table, no effect of intravenous steroid
therapy followed by radiotherapy was found within the
right eye, as assessed by ophthalmologic examination (no
statistical significance).
Based on the table, no effect of intravenous steroid
therapy followed by radiotherapy was found within the
left eye, as assessed by ophthalmologic examination (no
statistical significance).
Treatment results as assessed by computed tomography
(CT) of the retrobulbar areas.
Treatment efficacy measured with CT of retrobulbar
areas is presented in Table 7.
As shown in the table, no improvement was achieved
within the right eye after the combined treatment, as
assessed by computed tomography. Some improvement
Fig. 1 The arrangement of beams and the dose distribution during
irradiation of the retrobulbar area in Graves-Basedow disease
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reduction and decrease of optic nerve oedema. However, this
observation is based on a relatively small group of patients.
Comparison of treatment results
Improvement after the treatment of malignant exophthal-
mos was mostly of subjective nature. Therefore, evaluation
of efficacy of particular treatment methods was limited to
the patient self-reported results (Table 8).
As demonstrated in the table above, the highest efficacy
with respect to improvement of all ocular symptoms was
found after the combined treatment. Taking into consider-
ation the fact that the combined treatment of ophthalmop-
athy was the most effective one, the effect of prognostic
factors on the results of this treatment was studied. It was
shown that females and non-diabetic patients respond
favourably to the combined treatment (Tables 9 and 10).
Such factors as patient age, ocular symptoms duration,
smoking and thyroid function did not affect treatment
results (no statistical significance was demonstrated).
Toxicity of radiotherapy
Acute reaction occurred in 11/121 patients (9.1%) during
radiotherapy. Symptoms of acute reactions are presented in
Table 11.
Acute reaction symptoms were mild to moderate and
transient. Acute reaction in the diabetic group was not
worse than average.
During follow-up after treatment completion in the
group of 106 patients, three cases of cataract were
diagnosed that were rather related to physiological ageing
process than to radiotherapy. No diabetic retinopathy was
found in the diabetic group.
Symptoms of late post-irradiation reaction are presented
in Table 12.
Discussion
Aetiology of ophthalmopathy is not fully understood;
therefore, its treatment is usually of palliative nature and
Table 2 Treatment results as assessed by ophthalmologic examination in the group of patients treated previously with intravenous steroids
(n=101)—the right eye
NOSPECT The right eye before steroid treatment The right eye after steroid treatment p (Mc Nemara test)
Soft tissues Normal 15/101 (14.8%) 15/42 (35.7%) 0.0059
Grade 3 1/101 (1.0%) 0/42 (0.0%) 0.5165
Grade 2 33/101 (32.7%) 0/42 (0.0%)
Grade 1 52/101 (51.5%) 27/42 (64.3%)
Not examined 0/101 (0.0%) 59/101 (58.4%)
Exophthalmos Normal 46/101 (45.5%) 18/42 (42.8%) 0.7678
Grade 3 2/101 (2.0%) 1/42 (2.4%) 0.8799
Grade 2 12/101 (11.9%) 5/42 (11.9%)
Grade 1 41/101 (40.6%) 18/42 (42.8%)
Not examined 0/101 (0.0%) 59/101 (58.4%)
Oculomotor muscles Normal 23/101 (22.8%) 12/42 (28.6%) 0.4639
Grade 3 6/101 (5.9%) 0/42 (0.0%) 0.1101
Grade 2 35/101 (34.7%) 11/42 (26.2%)
Grade 1 37/101 (36.6%) 19/42 (45.2%)
Not examined 0/101 (0.0%) 59/101 (58.4%)
Cornea Normal 88/101 (87.2%) 36/42 (85.7%) 0.8099
Grade 3 0/101 (0.0%) 0/42 (0.0%) 1.0000
Grade 2 0/101 (0.0%) 0/42 (0.0%)
Grade 1 13/101 (12.8%) 6/42 (14.3%)
Not examined 0/101 (0.0%) 59/101 (58.4%)
Visual acuity Normal 8/101 (7.9%) 1/42 (2.4%) 0.2191
Grade 3 0/101 (0.0%) 0/42 (0.0%) 1.0000
Grade 2 0/101 (0.0%) 0/42 (0.0%)
Grade 1 93/101 (92.1%) 41/42 (97.6%)
Not examined 0/101 (0.0%) 59/101 (58.4%)
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disease and of functional eye disorders as well as
improvement of patient’s appearance [11, 36, 73]. Diag-
nostic criteria, selection of the treatment method as well as
Graves ophthalmopathy treatment results are still the matter
of controversy [12, 18, 22, 25, 38, 48, 51, 57, 63, 64].
Diagnosis is based mainly on clinical data [4, 12, 33, 54,
62, 64]. In the analysed material, the most common
complaints (most 95% of patients) were related to exoph-
thalmos and in 75% of patients (89/121) ocular symptoms
were accompanied by hyperthyreosis. In the remaining 25%
of patients, orbital CT scan was necessary to explain the
Table 4 Treatment results as assessed by computed tomography (CT) of the retrobulbar areas in the group of patients treated previously with
intravenous steroid therapy (n=101)
Left eye after treatment
completion—improvement
Right eye after treatment
completion—improvement
Thickness of the superior rectus muscle 0/43 (0.0%) 0/43 (0.0%)
Thickness of the inferior rectus muscle 0/54 (0.0%) 0/48 (0.0%)
Thickness of the lateral rectus muscle 0/33 (0.0%) 0/28 (0.0%)
Thickness of the median rectus muscle 0/71 (0.0%) 0/68 (0.0%)
Fat tissue 1/21 (4.8%) 0/18 (0.0%)
Optic nerve 0/1 (0.0%) 0/0 (0.0%)
Lacrimal gland 0/1 (0.0%) 0/2 (0.0%)
numerator the number of patients with improvement, denominator the number of patients with particular symptoms at baseline
Table 3 Treatment results as assessed by ophthalmologic examination in the group of patients treated previously with intravenous steroids
(n=101)—the left eye
NOSPECT The left eye before steroid treatment The left eye after steroid treatment p (Mc Nemara)
Soft tissues Normal 14/101 (13.8%) 16/42 (38.1%) 0.0014
Grade 3 1/101 (1.0%) 0/42 (0.0%) 0.5165
Grade 2 32/101 (31.7%) 0/42 (0.0%)
Grade 1 54/101 (53.5%) 26/42 (61.9%)
Not examined 0/101 (0.0%) 59/101 (58.4%)
Exophthalmos Normal 54/101 (53.5%) 23/42 (54.8%) 0.8873
Grade 3 4/101 (3.9%) 0/42 (0.0%) 0.1965
Grade 2 12/101 (11.9%) 6/42 (14.3%)
Grade 1 31/101 (30.7%) 13/42 (30.9%)
Not examined 0/101 (0.0%) 59/101 (58.4%)
Oculomotor muscles Normal 15/101 (14.9%) 9/42 (21.4%)
Grade 3 5/101 (4.9%) 0/42 (0.0%) 0.3454
Grade 2 37/101 (36.6%) 12/42 (28.6%) 0.1465
Grade 1 44/101 (43.6%) 21/42 (50.0%)
Not examined 0/101 (0.0%) 59/101 (58.4%)
Cornea Normal 88/101 (87.1%) 33/42 (78.6%) 0.2017
Grade 3 1/101 (1.0%) 0/42 (0.0%) 0.5165
Grade 2 1/101 (1.0%) 0/42 (0.0%)
Grade 1 11/101 (10.9%) 9/42 (21.4%)
Not examined 0/101 (0.0%) 59/101 (58.4%)
Visual acuity Normal 6/101 (5.9%) 0/42 (0.0%) 0.1101
Grade 3 2/101 (2.0%) 0/42 (0.0%) 0.3576
Grade 2 0/101 (0.0%) 0/42 (0.0%)
Grade 1 93/101 (92.1%) 42/42 (100.0%)
Not examined 0/101 (0.0%) 59/101 (58.4%)
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diagnosis of Graves ophthalmopathy is evaluation of the
oculomotor muscles diameters with maximum normal
values of 4.9 mm (−/+0.5 mm) [64].
The decision concerning the treatment of malignant
exophthalmos must be based on assessment of two
elements: severity of the symptoms and the level of disease
control [3, 11]. An obvious reflection of disease severity is
a significantly limited field of vision related to infiltration
of the optic nerve, as well as significant exophthalmos [11].
A separate problem is the level of disease activity. It seems
that after a period of progression, malignant exophthalmos
enters the phase of partial remission followed by a
stationary period. Additionally, exophthalmos activity level
does not correlate with symptoms severity [11].
Glycocorticosteroids may be used in the oral (predni-
sone), retrobulbar/subconjunctival or intravenous (methyl-
prednisolone acetate) forms [11, 29, 44, 64, 73]. The
intravenous route seems to be the most effective one,
particularly with respect to the soft tissue symptoms and
optic neuropathy [9–11]. The effect of steroid therapy on
exophthalmos and eye globe mobility is only a minor one
[11]. Improvement is found in about 60% of patients with
infiltrative ophthalmopathy [11, 64, 73]. Additionally, this
treatment is associated with numerous side effects [11, 26,
29, 42, 44, 51, 53, 73].
The efficacy of radiotherapy alone in the treatment of
Graves ophthalmopathy is assessed to be about 60% [6, 20,
27, 30, 57, 58, 62, 64, 73]. In the discussed material, only
five patients were treated with radiotherapy alone. The
above treatment was mostly effective in elimination of eye
burning sensation and lacrimation, peribulbar tissue oedema
and pain and/or eye pushing-out sensation. The follow-up
ophthalmologic examination suggests improvement of
vision acuity and CT scan, improvement of optic nerve
condition. It could be accordant with literature data but the
relatively low number of the observed patients makes it
difficult to draw any conclusions [2, 19, 50].
In the discussed material, acute reaction to radiotherapy
occurred in 11/121 patients (9.1%) and it was transient in
nature. Radiation sequent reported in the literature such as:
palpebral erythema, periorbital and conjunctival oedema,
Table 5 Treatment results as assessed by ophthalmologic examination in the group of patients treated with steroids and full-dose radiotherapy
20 Gy/10 fractions (n=93)—the right eye
NOSPECT Right eye before treatment Right eye 12months after treatment p (Mc Nemara)
Exophthalmos Normal 42/93 (45.2%) 42/87 (48.3%) 0.2561
Grade 3 2/93 (2.1%) 0/87 (0.0%)
Grade 2 11/93 (11.8%) 12/87 (13.8%)
Grade 1 38/93 (40.9%) 33/87 (37.9%)
Not examined 0/93 (0.0%) 6/93 (6.45%)
Soft tissues Normal 14/93 (15.1%) 48/83 (57.8%) 0.1945
Grade 3 1/93 (1.1%) 0/83 (0.0%)
Grade 2 30/93 (32.3%) 2/83 (2.4%)
Grade 1 47/93 (50.5%) 33/83 (39.8%)
Not examined 0/93 (0.0%) 10/93 (10.8%)
Oculomotor muscles Normal 21/93 (22.6%) 43/83 (46.2%) 0.8200
Grade 3 6/93 (6.4%) 0/83 (0.0%)
Grade 2 33/93 (35.5%) 4/83 (4.3%)
Grade 1 34/93 (36.6%) 36/83 (38.7%)
Not examined 0/93 (0.0%) 10/93 (10.8%)
Cornea Normal 80/93 (86.0%) 79/83 (95.2%) 0.8816
Grade 3 0/93 (0.0%) 0/83 (0.0%)
Grade 2 0/93 (0.0%) 0/83 (0.0%)
Grade 1 13/93 (14.0%) 4/83 (4.8%)
Not examined 0/93 (0.0%) 10/93 (10.8%)
Visual acuity Normal 7/93 (7.5%) 4/83 (4.8%) 0.1046
Grade 3 0/93 (0.0%) 0/83 (0.0%)
Grade 2 0/93 (0.0%) 0/83 (0.0%)
Grade 1 86/93 (92.5%) 79/83 (95.2%)
Not examined 0/93 (0.0%) 10/93 (10.8%)
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mild in nature [14, 17, 34, 47, 52, 55, 60, 65, 73, 74].
Late complications following radiotherapy of retrobulbar
area include: retinopathy, cataract and radiation-induced
tumours [9, 13–15, 17, 23, 24, 26, 29, 42, 43, 45, 46, 51,
59, 61, 65, 66, 68, 73]. In the presented material, three cases
of cataract (three out of 106=2.8%) were reported that
however might have been related to the physiological ageing
process and not to radiotherapy. In the group of diabetic
patients (12/93=12.9%) no diabetic retinopathy was found
after the combined treatment. Until now, no secondary
tumours were found within the previously irradiated area.
At least two controlled studies showed that combination of
high-dose steroid therapy with radiotherapy is the most
Table 7 Treatment results as assessed by computed tomography (CT) of the retrobulbar areas in the group of patients treated with steroids and
full-dose radiotherapy 20 Gy/10 fractions (n=93)
Left eye after treatment
completion—improvement
Right eye after treatment
completion—improvement
Thickness of the superior rectus muscle 0/41 (0.0%) 0/41(0.0%)
thickness of the inferior rectus muscle 0/51 (0.0%) 0/45 (0.0%)
Thickness of the lateral rectus muscle 0/30 (0.0%) 0/26 (0.0%)
Thickness of the median rectus muscle 0/68 (0.0%) 0/63 (0.0%)
Fat tissue 2/21 (9.5%) 0/18 (0.0%)
Optic nerve 1/1 (100%) 0/0 (0.0%)
Lacrimal gland 0/1 (0.0%) 0/2 (0.0%)
numerator the number of patients with improvement, denominator the number of patients with particular symptoms before the treatment
Table 6 Treatment results as assessed by ophthalmologic examination in the group of patients treated with steroids and full-dose radiotherapy
20 Gy/10 fractions (n=93)—the left eye
NOSPECT Left eye before treatment Left eye 12months after treatment p (Mc Nemara)
Exophthalmos Normal 49/93 (52.7%) 48/86 (55.8%) 0.0698
Grade 3 3/93 (3.2%) 0/86 (0.0%)
Grade 2 12/93 (12.9%) 6/86 (7.0%)
Grade 1 29/93 (31.2%) 32/86 (37.2%)
Not examined 0/93 (0.0%) 7/93 (7.5%)
Soft tissues Normal 14/93 (15.0%) 41/74 (55.4%) 0.2942
Grade 3 1/93 (1.1%) 0/74 (0.0%)
Grade 2 29/93 (31.2%) 1/74 (1.4%)
Grade 1 49/93 (52.7%) 32/74 (43.2%)
Not examined 0/93 (0.0%) 19/93 (20.4%)
Oculomotor muscles Normal 15/93 (16.1%) 35/83 (42.2%) 0.3332
Grade 3 5/93 (5.4%) 0/83 (0.0%)
Grade 2 32/93 (34.4%) 5/83 (6.0%)
Grade 1 41/93 (44.1%) 43/83 (51.8%)
Not examined 0/93 (0.0%) 10/93 (10.8%)
Cornea Normal 80/93 (86.0%) 76/82 (92.7%) 0.8216
Grade 3 1/93 (1.1%) 0/82 (0.0%)
Grade 2 1/93 (1.1%) 0/82 (0.0%)
Grade 1 11/93 (11.8%) 6/82 (7.3%)
Not examined 0/93 (0.0%) 11/93 (11.8%)
Visual acuity Normal 6/93 (6.4%) 5/83 (6.0%) 0.1696
Grade 3 1/93 (1.1%) 1/83 (1.2%) 0.9700
Grade 2 0/93 (0.0%) 0/83 (0.0%)
Grade 1 86/93 (92.5%) 77/83 (92.8%)
Not examined 0/93 (0.0%) 10/93 (10.7%)
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Exophthalmos 16/22 (72.7%) 54/67 (80.6%) 0.4345
Oedema 15/22 (68.2%) 40/66 (60.6%) 0.5250
Diplopia 8/22 (36.4%) 38/63 (60.3%) 0.0523
Eye burning/tearing 10/20 (50.0%) 50/64 (78.1%) 0.0151
a
Pain/eye pushing-out sensation 13/17 (76.5%) 41/58 (70.7%) 0.6406
Visual acuity 4/12 (33.3%) 22/35 (62.8%) 0.0759
Colour vision 0/0 (0.0%) 5/5 (100%)
Table 9 Improvement of ocular
symptoms by sex in the group of
patients treated with the com-
bined method (n=93)
numerator thenumber ofpatients
with improvement, denominator
the number of patients (by sex)
with particular symptoms at
baseline
aStatistically significant difference
(p<0.05)
Table 8 Patient self-reported eye symptoms improvement by treatment method
Symptom Steroid therapy n=101 Combined therapy n=93 p (Fisher test)
AB
Unilateral or bilateral exophthalmos 49/97 (50.5%) 71/89 (79.8%) A/B 0.0000
Oedema of the peribulbar soft tissue 39/96 (40.6%) 56/88 (63.7%) A/B 0.0020
Diplopia 50/93 (53.8%) 47/85 (55.3%) A/B 0.8809
Eye burning/lacrimation 35/91 (38.5%) 61/84 (72.6%) A/B 0.0000
Pain and/or eye pushing-out sensation 27/81 (33.3%) 56/76 (73.7%) A/B 0.0000
Visual acuity 26/50 (52.0%) 26/47 (55.3%) A/B 0.8392
Colour vision 4/7 (57.1%) 5/6 (83.3%) A/B 0.5594
numerator the number of patients with improvement, denominator the number of patients reporting particular symptoms at baseline
Table 10 Improvement of ocular symptoms in diabetic and non-diabetic patients in the group treated with the combined method (n=93)
Symptom Diabetics improvement Non-diabetics improvement Chi square
Exophthalmos 6/11 (54.6%) 65/78 (83.3%) 0.0261
a
Oedema 6/12 (50.0%) 50/76 (65.8%) 0.2907
Diplopia 2/11 (18.2%) 44/73 (60.3%) 0.0089
a
Eye burning/tearing 5/12 (41.7%) 56/72 (77.8%) 0.0094
a
Pain/eye pushing-out sensation 5/9 (55.6%) 51/67 (76.1%) 0.1884
Visual acuity 3/6 (50.0%) 23/41 (56.1%) 0.7790
Colour vision 1/2 (50.0%) 4/4 (100%) 0.1213
numerator the number of patients with improvement, denominator the number of non-diabetics/diabetics with particular symptoms
aStatistically significant difference (p<0.05)
Table 11 Symptoms of acute reaction in the group of 121 patients
with Graves ophthalmopathy occurring during radiotherapy of
retrobulbar areas
Acute post-irradiation reaction n=121
Significant tearing and eyelid oedema 3 (2.5%)
Erythema in high-dose areas 3 (2.5%)
Slight tearing 2 (1.6%)
Erythema and eye burning sensation 1 (0.8%)
Aggravation of diplopia and worsening of visual acuity 1 (0.8%)
Aggravation of tearing and worsening of visual acuity 1 (0.8%)
Table 12 Symptoms of late post-irradiation reaction found during
follow-up after treatment completion in the group of 101 patients with
Graves ophthalmopathy
Late post-irradiation reaction n=101
Retinopathy 0 (0.0%)
Cataract 3 (2.8%)
Radiation-induced tumours 0 (0.0%)
8 j ocul biol dis inform (2010) 3:1–11effectivetreatmentofmalignantexophthalmos[5, 11, 41, 75].
In the analysed material, the vast majority of patients were
treated with the combined method (93/101). Based on the
follow-up ophthalmologic examination, it was shown the
intravenous steroid therapy followed by radiotherapy is
effective with respect to normalisation of soft tissue and
oculomotor muscles condition as well as exophthalmos
improvement.
The following factors are considered to worsen the
prognosis of ophthalmopathy: patient age above 50–
60 years, male sex, smoking, symptom duration, concom-
itant diabetes, hyperthyreosis [2, 5, 8, 9, 13, 14, 25, 26, 30,
32, 45, 49, 51, 52, 58, 59, 70]. The effect of these factors
was analysed in the group of patients treated with the most
effective method, i.e. with the combined method. Patient
age, symptom duration, smoking, TSH and fT4 levels did
not affect significantly the results of the malignant
exophthalmos treatment—in contrast to concomitant diabe-
tes and male sex.
Graves ophthalmopathy treatment available at present is
not fully satisfactory. Its efficacy is assessed to be about
60–80% [46, 51]. Therefore, new treatment methods are
tested. Use of cytokine antagonists, in particular, penthox-
iphyline, somatostatin analogues and colchicine seems to be
the most promising among them [10, 36, 64, 73].
However, the majority of centres consider combined
steroid and radiotherapy treatment to be, at present, the best
treatment method for Graves ophthalmopathy [31, 57, 64,
67, 73, 75].
Conclusions
1. Radiotherapy combined with steroid therapy in the
treatment of Graves ophthalmopathy seems to be an
effective treatment of malignant exophthalmos symp-
toms at strictly defined indications.
2. Radiotherapy is a well-tolerated treatment modality in
Graves ophthalmopathy.
3. Diabetes mellitus is a factor worsening prognosis in
Graves ophthalmopathy.
4. Female sex is a favourable prognostic factor in Graves
ophthalmopathy.
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